StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
A number of other equities analysts also recently commented on RGLS. HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday, January 25th. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 16th.
RGLS stock opened at $0.19 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 12.48 and a quick ratio of 12.48. The company has a 50 day moving average price of $0.26 and a 200 day moving average price of $0.31. Regulus Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $1.48. The stock has a market capitalization of $27.30 million, a PE ratio of -0.57 and a beta of 2.21.
Institutional investors have recently modified their holdings of the business. DAFNA Capital Management LLC acquired a new position in shares of Regulus Therapeutics during the fourth quarter worth $1,750,000. Asymmetry Capital Management L.P. raised its stake in Regulus Therapeutics by 94.9% during the fourth quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 1,329,553 shares during the last quarter. Morgan Stanley raised its stake in Regulus Therapeutics by 13.0% during the third quarter. Morgan Stanley now owns 564,462 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 64,837 shares during the last quarter. Geode Capital Management LLC increased its stake in Regulus Therapeutics by 13.8% in the third quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 81,551 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in Regulus Therapeutics by 38.8% in the third quarter. Commonwealth Equity Services LLC now owns 111,000 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 31,000 shares in the last quarter. Hedge funds and other institutional investors own 47.06% of the company’s stock.
About Regulus Therapeutics (Get Rating)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.